WuXi Biologics (Cayman) Inc. (BKK:WUXI06)

WuXi Biologics Statistics

Total Valuation

WuXi Biologics has a market cap or net worth of THB 621.96 billion. The enterprise value is 606.82 billion.

Market Cap	621.96B
Enterprise Value	606.82B

Important Dates

The next estimated earnings date is Wednesday, November 19, 2025.

Earnings Date	Nov 19, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-2.55%
Shares Change (QoQ)	-0.30%
Owned by Insiders (%)	0.54%
Owned by Institutions (%)	34.64%
Float	3.54B

Valuation Ratios

The trailing PE ratio is 32.69 and the forward PE ratio is 25.72.

PE Ratio	32.69
Forward PE	25.72
PS Ratio	6.84
PB Ratio	2.80
P/TBV Ratio	3.19
P/FCF Ratio	77.98
P/OCF Ratio	23.98
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.12, with an EV/FCF ratio of 76.08.

EV / Earnings	31.90
EV / Sales	6.63
EV / EBITDA	19.12
EV / EBIT	24.23
EV / FCF	76.08

Financial Position

The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.10.

Current Ratio	2.88
Quick Ratio	2.40
Debt / Equity	0.10
Debt / EBITDA	0.73
Debt / FCF	2.90
Interest Coverage	31.72

Financial Efficiency

Return on equity (ROE) is 10.50% and return on invested capital (ROIC) is 6.64%.

Return on Equity (ROE)	10.50%
Return on Assets (ROA)	5.89%
Return on Invested Capital (ROIC)	6.64%
Return on Capital Employed (ROCE)	10.57%
Revenue Per Employee	7.24M
Profits Per Employee	1.52M
Employee Count	12,575
Asset Turnover	0.34
Inventory Turnover	6.36

Taxes

In the past 12 months, WuXi Biologics has paid 5.59 billion in taxes.

Income Tax	5.59B
Effective Tax Rate	20.03%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	578,603

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, WuXi Biologics had revenue of THB 90.92 billion and earned 19.02 billion in profits. Earnings per share was 4.48.

Revenue	90.92B
Gross Profit	38.78B
Operating Income	24.89B
Pretax Income	27.90B
Net Income	19.02B
EBITDA	30.85B
EBIT	24.89B
Earnings Per Share (EPS)	4.48

Balance Sheet

The company has 56.85 billion in cash and 23.15 billion in debt, giving a net cash position of 33.70 billion.

Cash & Cash Equivalents	56.85B
Total Debt	23.15B
Net Cash	33.70B
Net Cash Per Share	n/a
Equity (Book Value)	222.44B
Book Value Per Share	50.09
Working Capital	72.35B

Cash Flow

In the last 12 months, operating cash flow was 25.94 billion and capital expenditures -17.96 billion, giving a free cash flow of 7.98 billion.

Operating Cash Flow	25.94B
Capital Expenditures	-17.96B
Free Cash Flow	7.98B
FCF Per Share	n/a

Margins

Gross margin is 42.65%, with operating and profit margins of 27.38% and 20.92%.

Gross Margin	42.65%
Operating Margin	27.38%
Pretax Margin	30.69%
Profit Margin	20.92%
EBITDA Margin	33.93%
EBIT Margin	27.38%
FCF Margin	8.77%

Dividends & Yields

WuXi Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.55%
Shareholder Yield	2.55%
Earnings Yield	3.06%
FCF Yield	1.28%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

WuXi Biologics has an Altman Z-Score of 5.11 and a Piotroski F-Score of 8.

Altman Z-Score	5.11
Piotroski F-Score	8